EU Competition Law and IP Rights in the Pharma & Biotech Sectors

Precio especial 178,10 € Precio habitual 187,47 €
Disponible (en stock)
Nombre del producto:
EU Competition Law and IP Rights in the Pharma & Biotech Sectors
Fecha de edición:
30 may. 2021
Número de Edición:
Bjorn Lundqvist, Timo Minssen / Pierce, Justin
Lugar de edición:

This book provides an analytical overview of the function and application of competition law and intellectual property (IP) law in the pharmaceutical and biotechnology sectors. It offers a general introduction to the foundations and principles of competition law and its interface with intellectual property law, as well as a brief scientific preface, and an overview of the competitive environment and innovation system in which the pharmaceutical industry operates. It presents and discusses practices and conduct that have been identified as allegedly anticompetitive, analysing them from the perspectives of both competition and intellectual property law. The book discusses the issues raised by the 2009 EU (European Union) Pharmaceutical Sector Inquiry in depth, with reference to the case law that has developed since the Inquiry was published. In particular, the book scrutinises the cases and investigations in the European Union and United States regarding 'pay-for-delay' and other settlement agreements, the misuse of the patent systems, the misuse of the courts, and the alleged misuse of the regulatory system by pharmaceutical companies. It considers co-marketing, co-promotion, and co-branding from an antitrust perspective. There is discussion of different patent strategies and whether they violate competition law or patent law. The book also covers the introduction of the unitary patent in Europe, the Unified Patent Court, and their implications for the utilization of competition law.

The book describes and explains developments relating to competition law and intellectual property law in the relevant sectors, putting them into context from both a theoretical and practical perspective. It addresses important competition law issues that arise where IP rights are acquired and utilised in Europe. It also contains useful guidance on how to deal with competition issues that arise within the intellectual property framework, and discusses when competition law is applicable and when exemption under intellectual property law may be applied.

This comprehensive and detailed analysis is invaluable to practitioners, researchers, and students alike.

Escribir Su propia reseña
Estás revisando:EU Competition Law and IP Rights in the Pharma & Biotech Sectors
Su valoración